

1 **A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the Safety,**
2 **Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-**
3 **COV1901(Beta) SARS-CoV-2 Vaccine in Adults**

4 Chia En Lien^{1,2}, Ming-Che Liu³, Ning-Chi Wang⁴, Luke Tzu-Chi Liu¹, Chung-Chin Wu¹, Wei-Hsuan Tang¹, Wei-
5 Cheng Lian¹, Kuan-Ying A. Huang^{5,6,7*}, Charles Chen^{1,8*}.

6

7 ¹Medigen Vaccine Biologics Corporation, Taipei, Taiwan

8 ²Institute of Public Health, National Yang-Ming Chiao Tung University, Taipei City, Taiwan

9 ³Clinical Research Centre, Taipei Medical University Hospital Taipei, Taiwan

10 ⁴Tri-Service General Hospital, Taipei, Taiwan

11 ⁵Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan, Taiwan.

12 ⁶Genomics Research Center, Academia Sinica, Taipei, Taiwan.

13 ⁷Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan,
14 Taiwan.

15 ⁸College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.

16 *Co-Corresponding authors:

17 Kuan-Ying A. Huang: arthur1726@cgmh.org.tw;

18 Charles Chen: charles@medigenvac.com

19 **Keywords:** COVID-19; SARS-CoV-2; SARS-CoV-2 vaccine; MVC-COV1901; booster vaccination; SARS-CoV-2 Beta
20 variant booster vaccine, Omicron variant

21

22

23

24 **Abstract**

25 **Background**

26 The use of variant-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
27 vaccine as a booster is being evaluated to overcome reduced neutralisation of variants induced by
28 the original SARS-CoV-2 vaccine and waning protection over time.

29 **Methods**

30 This is a phase one, prospective, randomized, and open-labeled trial to study the safety and
31 immunogenicity of a booster dose consisting of a subunit vaccine based on the stabilized prefusion
32 SARS-CoV-2 spike protein, MVC-COV1901 or its Beta version, MVC-COV1901-Beta. One-
33 hundred and seven participants aged ≥ 18 and < 55 years, who received two or three prior doses of
34 MVC-COV1901 vaccines, were enrolled and were to receive a booster dose of either 15 mcg of
35 MVC-COV1901, 15 mcg or 25 mcg of MVC-COV1901-Beta in 1:1:1 ratio. The primary
36 endpoints were the incidences of adverse events and immunogenicity of the booster dose from
37 Visit 2 (the day of the booster) to Visit 5 (four weeks after the booster). Cellular immunity was
38 also investigated with memory B cell (MBC) and T cell assays.

39 **Findings**

40 Adverse reactions after either MVC-COV1901 or MVC-COV1901-Beta booster doses after
41 two or three doses of MVC-COV1901 were comparable and mostly mild and transient. At four
42 weeks after the booster dose, participants with two prior doses of MVC-COV1901 exhibited
43 numerically higher levels of neutralising antibodies against SARS-CoV-2 or Beta variant than
44 participants with three prior doses of MVC-COV1901 regardless of the type of booster used.
45 However, compared to 15 mcg of MVC-COV1901, 25 mcg of MVC-COV1901-Beta significantly
46 improved neutralising antibody titre against Beta variant and BA.4/BA.5 Omicron variant
47 pseudoviruses. The booster dose also significantly increased the proportion of spike-specific

48 MBCs, including those of Beta and Omicron variants.

49 **Interpretation**

50 MVC-COV1901-Beta can be effectively used as a booster dose against SARS-CoV-2,
51 including the circulating BA.4/BA.5 Omicron variant.

52 **Funding**

53 Medigen Vaccine Biologics Corporation

54

55 **Introduction**

56 The vaccine efficiency against the SARS-CoV-2 virus is hampered by the circulation of
57 variants resistant to antibody neutralisation imparted by the SARS-CoV-2 vaccine based on the
58 ancestral strain [1, 2]. As of August 2022, WHO has updated its SAR-CoV-2 list of variants of
59 concern (VoC) to consist solely of the Omicron variant and its subvariants [3]. The implication of
60 the Omicron variants as the circulating VoC is that primary series and even booster vaccination
61 with currently available vaccines have shown to perform poorly against the current circulating
62 Omicron variant and its subvariants in general, including the BA.2 and BA.4/BA.5 subvariants [4,
63 5]. Various Omicron variant-based vaccines have been developed or are in development, including
64 a monovalent mRNA vaccine based on the Omicron variant by Pfizer/BNT is in the midst of a
65 phase 2/3 clinical trial that claimed to have demonstrated effective neutralisation against the BA.1
66 subvariant and to a lesser extent, the BA.4 and BA.5 subvariants [6]. Recently, citing a strong
67 immune response generated against the ancestral virus and the BA.1 Omicron variant, as well as a
68 good immune response against the BA.4 and BA.5 subvariants, the United Kingdom became the
69 first country in the world to approve a bivalent COVID-19 booster vaccine for adults (Moderna
70 bivalent mRNA vaccine based on the ancestral SARS-CoV-2 and the Omicron variant) [7].

71 MVC-COV1901 is a subunit COVID-19 vaccine based on the stable prefusion spike protein
72 S-2P of the ancestral SARS-CoV-2 and adjuvanted with CpG 1018 and aluminum hydroxide [8].
73 We have previously shown that three doses of MVC-COV1901 can improve neutralising antibody
74 response against live SARS-CoV-2 and Omicron variant pseudovirus [9]. We first demonstrated
75 the ability of the Beta variant version of S-2P to protect hamsters from the Delta variant challenge
76 and have also shown improved neutralising antibody levels against a broad spectrum of variants,
77 including the current Omicron variant [10]. In the current study, two groups of participants who
78 have received either two or three doses of MVC-COV1901 were administered with a booster dose
79 of either original MVC-COV1901 or MVC-COV1901 based on the Beta variant in two different
80 dose levels (MVC-COV1901-Beta). Reacogenicity and immunogenicity against the original
81 SARS-COV-2 and beta variant were examined after the booster dose. To investigate the levels of
82 neutralising antibodies against the Omicron subvariants, we have also conducted a pseudovirus
83 neutralisation assay with the Omicron BA.4/BA.5 pseudovirus.

84

85 **Methods**

86 **Study design and participants**

87 This was a prospective, randomized, open-labeled phase I study to evaluate the safety,
88 tolerability, and immunogenicity of booster dose with MVC-COV1901 or MVC-COV1901-Beta
89 SARS-CoV-2 vaccine in adult participants. Approximately 120 participants were screened and
90 participants who received two or three prior doses of MVC-COV1901 were respectively placed into
91 Group A or Group B. Eligible participants were healthy adults aged from 18 (inclusive) to 55 years
92 who have completed two or three doses of MVC-COV1901 vaccination, with 1st and 2nd doses within
93 12 weeks, 2nd and 3rd doses between 12 to 24 weeks (for Group B only), and with the latest dose at
94 least 84 days before randomization, and did not receive any other investigational or approved COVID-

95 19 vaccines.

96 The trial protocol and informed consent form were approved by the Taiwan Food and Drug
97 Administration and the institutional review boards of the Taipei Medical University Hospital
98 (Taipei, Taiwan) and the Tri-Service General Hospital (Taipei, Taiwan). The trial was conducted
99 in compliance with the principles of the Declaration of Helsinki and Good Clinical Practice. Safety
100 data was monitored by an independent data and safety monitoring board (DSMB). This trial was
101 registered at ClinicalTrials.gov: NCT05216601.

102 **Randomisation and masking**

103 The randomization of each group was stratified based on site to three treatment arms, 15 mcg of
104 MVC-COV1901, or 15 mcg or 25 mcg of MVC-COV1901-Beta in a 1:1:1 ratio. Blinding was not
105 performed as this was an open-labeled study.

106 **Procedure and outcomes**

107 The investigative product MVC-COV1901 contained 15 mcg of SARS-CoV-2 S-2P protein
108 adjuvanted with CpG 1018 750 mcg and aluminium hydroxide 375 mcg, while MVC-COV1901-
109 Beta contained either 15 or 25 mcg of SARS-CoV-2 Beta variant S-2P protein adjuvanted with 750
110 mcg CpG 1018 and 375 mcg aluminium hydroxide. Booster doses were administered as
111 intramuscular injections of 0.5 mL of the vaccine in the deltoid region of the non-dominant arm,
112 identical to the administration of the original MVC-COV1901 vaccine as primary series [9].

113 The primary safety endpoint of this study was the incidence of adverse events within 28 days
114 of the booster administration. The primary immunogenicity endpoint was the levels of neutralising
115 antibody titres at Visit 5 (4 weeks after the booster dose) and anti-spike immunoglobulin G (IgG)
116 antibody titres at Visits 4 (2 weeks after the booster dose) and 5. Safety was assessed by incidences
117 of solicited AEs for up to seven days after each vaccination and unsolicited AEs for up to 28 days
118 after each vaccination. Other AEs, such as serious adverse events (SAEs) and adverse events of

119 special interest (AESI), were recorded within the study period. Immunogenicity was assessed by
120 neutralising assay with the original (WT) SARS-CoV-2 and Beta variant and IgG titres in terms of
121 geometric mean titre (GMT) and GMT ratio. Pseudovirus neutralising assays with the Omicron
122 variant (BA.4/BA.5 subvariant) pseudovirus were performed with samples from Visits 2 (baseline)
123 and 5.

124 Neutralising antibody titres against live SARS-CoV-2 virus were performed with original
125 SARS-CoV-2 (hCoV-19/Taiwan/4/2020, GISAID EPI_ISL_411927) and Beta variant (B.1.351,
126 hCoV-19/Taiwan/1013) [11]. Briefly, two-fold serial dilutions of serum samples were mixed with
127 equal volumes of 100 TCID₅₀/50 µL of virus and incubated at 37 °C for one hour. After incubation,
128 the mixtures were added to Vero E6 cells and incubated at 37 °C for four to five days. The
129 neutralising antibody titre was defined as the reciprocal of the highest dilution capable of
130 neutralising 50% of the infection (NT₅₀) calculated using the Reed-Muench method. Anti-SARS-
131 CoV-2 spike immunoglobulin (IgG) levels were measured by enzyme-linked immunosorbent assay
132 (ELISA) using custom-made 96-well plates coated with S-2P antigen [10].

133 Pseudotyped lentivirus with spike proteins of Wuhan wildtype or Omicron (BA.4/BA.5, both
134 possess identical spike protein sequences) variant was used in pseudovirus neutralisation assay
135 conducted as reported previously [8]. HEK-293-hAce2 cells were inoculated with two-fold serial
136 dilutions of serum samples mixed with equal volumes of pseudovirus. Fifty percent inhibition
137 dilution titres (ID₅₀) were calculated with uninfected cells as 100% neutralisation and cells
138 transduced with the virus as 0% neutralisation. The mutations for the Omicron variant
139 (BA.4/BA.5) used in the spike sequence for pseudovirus construction were derived from the WHO
140 source: T19I, del24-26, A27S, del69-70, G142D, V213G, G339D, S371F, S373P, S375F, T376A,
141 D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y,
142 Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K [3].

143 Frozen peripheral blood mononuclear cells were thawed and used to set up the memory B
144 cell (MBC) assay. Peripheral blood mononuclear cell (PBMC) suspension in RPMI 1640-10%
145 (v/v) fetal calf serum was incubated with an equal volume of polyclonal mitogens mixture,
146 pansorbin cells (1/2500)(heat-killed, formalin-fixed *Staphylococcus aureus*, Sigma-Aldrich, USA),
147 ODN 2006 (5 mcg/mL)(Class B CpG oligonucleotide, InvivoGen, USA), and pokeweed mitogen
148 (40 ng/mL)(Lectin from *Phytolacca americana*, Sigma-Aldrich, USA), at 37°C, 5% CO₂ incubator
149 for 6 days. After incubation, cultured PBMCs were harvested, washed and resuspended in RPMI
150 1640-10% (v/v) fetal calf serum for following enzyme-linked immunospot assay.

151 For the enzyme-linked immunospot (ELISpot) assay, 96-well PVDF membrane, 96-well
152 multiscreen filter plate (Millipore, USA) was coated with SARS-CoV-2 spike-2P wild type,
153 SARS-CoV-2 spike-2P Beta variant or SARS-CoV-2 spike-2P Omicron variant, at 4°C, overnight.
154 The wells coated with PBS were negative controls and those coated with goat anti-human Ig
155 antibody (Sigma-Aldrich, USA) were used to detect all IgG, IgM and IgA-secreting B cells. The
156 coated plate was washed with PBS and blocked with RPMI 1640-10% (v/v) fetal calf serum at
157 37°C for 2 hours. After washing, cultured PBMC suspension was added to wells (200,000 cultured
158 PBMCs for spike- or PBS-coated well and 5,000 cultured PBMCs for anti-human Ig-coated well)
159 and incubated at 37°C, 5% CO₂ incubator for 16 to 18 hours. After washing, the plate was
160 incubated with goat anti-human IgG, IgM or IgA conjugated with alkaline phosphatase
161 (Calbiochem, USA) at 37°C for 1 hour. After washing, the plate was developed with an alkaline
162 phosphatase conjugate substrate kit (Bio-Rad, USA) at room temperature. Spot-forming cells were
163 detected and measured with an automatic ELISpot reader.

164 T cell cytokine assay was performed as described previously using ELISpot assays specific
165 for IFN- γ and IL-4 [12]. Thawed and rested PBMCs were dispensed at 1×10^5 cells per well for
166 IFN- γ ELISpot assay (Human IFN- γ ELISpot Kit, MABTECH) or 2×10^5 cells per well for IL-4
167 ELISpot assay (Human IL-4 ELISpot Kit, MABTECH). Cells were stimulated with a pool of

168 peptides derived from ancestral Wuhan strain (PepTivator SARS-CoV-2 Prot_S WT Reference
169 Pool, Miltenyi Biotech, Germany) and Beta variant SARS-CoV-2 (PepTivator SARS-CoV-2
170 Prot_S B.1.351 Mutation Pool, Miltenyi Biotech, Germany) and incubated at 37 °C for 24 to 48 h.
171 CD3-2 monoclonal antibody were used as the positive control for stimulation. Spots were counted
172 using the CTL automatic ELISpot reader S6 Macro Analyzer (ImmunoSpot, USA). Results were
173 expressed as spot forming units (SFU) per million PBMC.

174 **Statistical analysis**

175 As this was an exploratory phase 1 clinical study, the sample size was arbitrarily determined
176 and was not derived from a statistical estimation method and a statistical hypothesis was not used
177 for sample size calculation in this study. All results are presented using descriptive statistics. GMT,
178 GMT ratio and corresponding CI are calculated using an ANCOVA model with baseline log-titres,
179 BMI (<30 or >=30 kg/m²) and comorbidity (yes or no) and sex (male or female) as a covariate.
180 GMT ratio is defined as the geometric mean of fold increase of post-study intervention titres over
181 the baseline titres. Prism 6.01 (GraphPad) was used for statistical analysis. Kruskal-Wallis with
182 corrected Dunn's multiple comparisons test was used for comparison of means of the non-
183 parametric dataset (Figures 3 and 5), while the Mann-Whitney test was used to compare MBC
184 frequencies at two-time points in Figures 5B and C. Linear regression was used to model the
185 relationship between neutralization titre and IgG MBC frequency in Figure 5D

186 The following groups were used for the study analysis: Safety Set included all randomized
187 participants who received the study intervention; the Full analysis set (FAS) included all
188 randomized participants who received the study intervention, irrespective of their protocol
189 adherence and continued participation in the study. Pre protocol set (PPS) included all participants
190 in the FAS who receive the planned dose of randomized study intervention, and up until Visit 5, did
191 not have laboratory-confirmed COVID-19 infection, were negative for SARS-CoV-2 anti-N tests,

192 and did not have major protocol deviation that was judged to impact the critical immunogenicity
193 data.

194

195 **Results**

196 Between May and July 2022, a total of 129 adult participants were screened and 107 eligible
197 participants were split into groups of 45 and 62 for Groups A and B, respectively (Figure 1). In
198 terms of the demographics of the participants, all groups had similar mean age and BMI levels,
199 although the gender ratios were less equal among the groups (Table 1). The mean intervals
200 between the last dose of MVC-COV1901 and the booster dose were longer in Group A (223.3 to
201 294.5 days) than in Group B (120.9 to 128.0 days). Solicited adverse events (SAEs) are
202 summarized in Figure 2 and tabulated in Tables S1 and S2. Unsolicited AEs are summarized in
203 Table S3. No SAE (grade 3 AEs or higher) or AESI related to the vaccine have been reported after
204 the booster dose. The most common solicited local and systemic effects after any booster dose
205 were pain/tenderness (60.0~73.3% in Group A and 57.1~70.0% in Group B) and malaise/fatigue
206 (33.3~53.3% in Group A and 28.6~40.0% in Group B), respectively. While erythema/redness (two
207 participants in Group A) and fever (two participants in Group A and one participant in Group B)
208 were the least common AEs. The safety profile and incidences of AEs were comparable in both
209 groups (Figure 2, Tables S1-S3).

210 At V5, Group A participants had numerically higher levels of neutralising antibodies against
211 the ancestral SARS-CoV-2 (WT), with the GMTs ranging from 1352.0 to 3602.8 for Group A
212 compared to 867.9 to 1125.0 for Group B; however, the differences were not significant between
213 the groups (Figure 3A and Table S4). Similar results were observed for the Beta variant, with the
214 neutralizing antibody GMTs for Group A ranging from 225.6 to 1476.9 compared to 147.1 to
215 459.2 in Group B. In Group A, 25 mcg of MVC-COV1901-Beta significantly ($p < 0.05$) increased

216 the level of neutralizing antibody against the Beta variant (1476.9 [95% CI 806.4 - 2704.8])
217 compared to 15 mcg of MVC-COV1901 (225.59 [128.1 – 397.2]) (Figure 3A and Table S4).
218 However, in Group B, 15 mcg of MVC-COV1901-Beta induced the highest level of neutralizing
219 antibody against the Beta variant (459.2 [95% CI 322.2 – 654.6]) compared to 15 mcg of MVC-
220 COV1901 (147.1 [102.3 – 211.6]) and 25 mcg of MVC-COV1901-Beta (323.8 [227.7 – 460.4])
221 (Figure 3A and Table S4). All participants had high levels of anti-spike IgG at Visits 4 and 5,
222 regardless of the type of booster received or the number of prior doses of MVC-COV1901 (Figure
223 3B). When calculating the GMT ratio of neutralising antibody and IgG titres at V5 or V4 against
224 the baseline (V2) titres, Group B had a minimal increase in GMT ratio compared to Group A
225 (Figure 3C and Table S4). The increase of GMT ratio against the Beta variant was most noticeable
226 in the 25 mcg MVC-COV1901-Beta dosage group for Group A, with V5/V2 neutralising antibody
227 GMT ratio of 202.9 [110.8 – 371.5] and V5/V2 IgG GMT ratio of 49.4 [30.9 – 79.1] in the 25 mcg
228 MVC-COV1901-Beta dosage group compared to for V5/V2 neutralising antibody GMT ratio of
229 31.0 [17.6 – 54.6] and V5/V2 IgG GMT ratio of 20.2 [13.1 – 31.1] in the 15 mcg MVC-COV1901
230 dosage group (Figure 3C and Table S4).

231 The immunogenicity of booster dose against the Omicron variant was investigated with the
232 BA.4/BA.5 pseudovirus neutralization assay. In both groups at V4, all types of booster doses had
233 uniformly high levels of neutralising antibodies against the WT pseudovirus (Figure 4). Against
234 the BA.4/BA.5 pseudovirus, 25 mcg of MVC-COV1901-Beta elicited a significantly higher ($p <$
235 0.01) level of neutralising antibody (ID_{50} 425.7 [272.8 – 664.2]) than 15 mcg of MVC-COV1901
236 (ID_{50} 139.1 [76.2 – 254.1]) (Figure 4, Table S4). In Group B, this was not observed and instead,
237 all types of booster doses resulted in similar levels of neutralising antibodies.

238 Prior to the booster dose at V2, 15 of 18 (83%) Group A subjects had detectable SARS-
239 CoV-2 spike-specific IgG memory B cells (MBCs), in which WT, Beta, or Omicron BA.1 spike-
240 specific IgG cells accounted for around 0.5 to 0.6% of total IgG cells in the peripheral blood

241 (Figure 5A, B; Figure S1). A total of 17 of 18 (94%) Group B subjects had detectable spike-
242 specific IgG MBCs (Figure 5B; Figure S1). Group B subjects had significantly higher pre-existing
243 wild type, Beta and Omicron BA.1 spike-specific IgG MBC frequencies compared to those of
244 group A subjects (wild type, 0.6 ± 0.1 v.s. 1.4 ± 0.2 , $p = 0.002$; Beta, 0.6 ± 0.1 v.s. 1.3 ± 0.2 , $p = 0.005$;
245 Omicron, 0.5 ± 0.1 v.s. 0.9 ± 0.1 , $p = 0.029$, Mann-Whitney test). Pre-existing spike-specific IgM
246 and IgA MBCs were detected in both groups as well, but there is no significant difference in the
247 frequency between the two groups (Fig. 5B).

248 After the booster dose, a significant increase in spike-specific MBC frequency was observed
249 in both Group A and B subjects, of which IgG MBC response dominated (Figure 5B), followed by
250 IgM or IgA MBC responses, indicating the elicitation of immune memory to SARS-CoV-2 spike.
251 At two weeks after the booster dose (V4), the WT, Beta, and Omicron BA.1 spike-specific IgG
252 MBC frequency averaged 6.1 ± 1.3 , 6.0 ± 1.2 , and 4.8 ± 1.3 of total IgG cells ($P < 0.0001$ for all
253 comparisons between pre-existing and elicited responses), respectively, in Group A (Figure 5B).
254 Enhanced spike-specific IgG MBC responses imparted by the booster were also observed in
255 Group B at day 14 (Figure 5B). Although Group B subjects produced a relatively lower V4 wild
256 type, Beta or Omicron BA.1 spike-specific IgG MBC frequency compared to that of Group A, the
257 difference was not statistically significant.

258 All treatment groups in Group A elicited a significantly higher WT, Beta or Omicron BA.1
259 spike-specific IgG MBC frequency than that at the baseline (Figure 5C). Those with Beta 15 mcg
260 booster produced a relatively higher wild type, Beta or Omicron BA.1 spike-specific IgG MBC
261 frequency at V4 than those with wild type or Beta 25 mcg booster, but the difference was not
262 statistically significant (Figure S2).

263 Within Group B, those with the original MVC-COV1901 booster produced an elevated
264 spike-specific IgG MBC frequency at V4, but did not result in significant increases in Beta or

265 Omicron BA.1 spike-specific MBC frequency (Figure 5C). Those with Beta 15 mcg booster
266 produced a significantly higher Beta spike-specific IgG MBC response at V4 and those with Beta
267 25 mcg booster produced significantly higher wild type, Beta and Omicron BA.1 spike-specific
268 IgG MBC frequencies at V4 that those at the baseline (Figure 5C). Nevertheless, similar WT, Beta
269 or Omicron BA.1 spike-specific IgG MBC frequencies were detected among three subgroups at
270 V4 (Figure S2).

271 Significant correlations between spike-specific MBC frequency and serological
272 neutralisation titre were observed for Group A and B subjects, indicating a potential role of spike-
273 specific B cell response in the development of antibody immunity upon SARS-CoV-2
274 immunization (Figure 5D; Figure S3).

275 T cell immune response was investigated by the production of interferon-gamma (IFN- γ)
276 and IL-4 for Th-1 and Th-2 responses, respectively. Results indicated a generally Th-1-biased T
277 cell response based on a higher amount of IFN-g induction than IL-4 induction, particularly in
278 Group A (Figure S4).

279

280 **Discussion**

281 This was the first clinical trial to investigate the safety and immunogenicity of a Beta
282 variant version of the CpG 1018-adjuvanted subunit SARS-CoV-2 vaccine, MVC-COV1901-
283 Beta, for its use as a heterologous booster dose following two or three doses of MVC-COV1901.
284 The safety profile of MVC-COV1901-Beta was in line with that of the original MVC-COV1901,
285 with pain/tenderness and malaise/fatigue as the most common adverse events while incidences of
286 fever were rarely reported (Figure 2) [9, 11].

287 In this study, boosting with MVC-COV1901-Beta with 25 mcg of Beta S-2P protein has
288 shown to significantly increase the neutralising antibody titre against the Beta variant as well as

289 the Omicron variant pseudovirus compared to boosting with 15 mcg of MVC-COV1901
290 following two doses of MVC-COV1901 (Figures 3 and 4). The finding is consistent with our
291 previous study, though, with the prototype antigen, which showed the increase of cross-
292 reactivities against VoCs when antigen amount increases while adjuvant remained unchanged
293 [13]. However, the levels of increase in neutralising antibody titre were lower in participants who
294 had received three doses of MVC-COV1901 prior to boosting (Group B) (Figures 3 and 4). We
295 attribute this to the differences in intervals between the last dose of MVC-COV1901 to the
296 booster dose, which in Group A ranged from a mean of 223.3 to 294.5 days, while ranged from a
297 mean of 109.2 to 128 days for Group B (Table 1). As less time has passed in Group B following
298 the last vaccination compared to Group A, the baseline titres for Group B were higher and the
299 boosting effect was less dramatic than that of Group A. In addition, in the results from our
300 previous study in the course of three doses of MVC-COV1901 vaccination, the rate of
301 neutralising antibody titre decay was slower after the third (booster) dose compared to the second
302 dose, which could also explain the higher baseline titres in Group B [9].

303 Studies before the emergence of the Omicron variant demonstrated a correlation between
304 the neutralizing antibody levels and the protection from infection [14]. However, the correlation
305 between the neutralizing antibody level and the protection from the Omicron variant infection is
306 yet to be determined. The vastly decreased protection against infection due to the vaccine escape
307 strain reported from vaccine effectiveness studies indicates that none of the homologous
308 regimens based on the prototype vaccine could be an optimal and durable tool to control the
309 transmission and infection [1]. The revised target product profile for the COVID-19 vaccine
310 published by WHO in April 2022 reflected the paradigm shift and emphasized the role of a
311 booster vaccine for protection against severe outcomes, including hospitalization, and long
312 COVID [15]. T-cell immune response against SARS-CoV-2 is known to play a crucial role in
313 improving the breadth of coverage against VoCs, and offering protection against severe

314 outcomes [16]. In patients with immune-mediated inflammatory diseases on B cell depleting
315 therapies breakthrough infections were frequent and associated with severe outcomes [17]. These
316 findings indicate that to achieve the revised target product profile of the COVID vaccine under
317 the era of the Omicron variant, the roles of T and B cell immune responses should be looked at
318 as a whole.

319 This is the first study to report Omicron-specific memory B cell activities after a Beta
320 variant version of the CpG 1018-adjuvanted subunit vaccine SARS-CoV-2 vaccine. The cellular
321 immunity after the booster dose was shown by the proliferation and expansion of spike-specific
322 MBCs, indicating immune memory recall induced by the booster dose (Figure 5). Regardless of
323 the type of booster used, higher proportions of MBC with IgGs specific to WT, Beta, or Omicron
324 spikes were seen after the booster dose, thus MBCs recalled by the booster dose are cross-
325 reactive against all strains tested (Figures 5B and C). The dominance of IgG MBC expansion
326 also reflects the involvement of germinal center reaction and the establishment of spike-specific
327 B cell pools, similar to the findings after the mRNA-1273 boost [18]. The potency and epitope
328 recognition of spike-specific B cell repertoire elicited by subunit vaccine boost, especially those
329 cross-reacting with the Omicron variant, require further investigation.

330 While homologous booster after two doses of vaccination provided higher protection
331 against hospitalization against the Omicron variant, the vaccine efficiencies against infection still
332 remained poor [19, 20]. To better counter the circulating variants, updated version of vaccines,
333 including MVC-COV1901-Beta, have been developed and is in the progress of the deployment.
334 The recently approved bivalent mRNA-1273.214 based on the ancestral and Omicron strains
335 imparted a 5.4-fold increase in neutralising antibody response against the BA.4/BA.5 subvariants
336 in a phase 2/3 clinical trial in participants with three prior doses of mRNA-1273 [21].
337 Pfizer/BioNTech have developed Omicron-adapted monovalent and bivalent versions of the
338 vaccine which elicited a 13.5 to 19.6-fold increase and 9.1 to 10.9-fold increase, respectively, in

339 neutralizing antibody titers against the Omicron BA.1 variant in a phase 2/3 trial given as a
340 fourth dose [6]. Another monovalent adjuvanted subunit vaccine by Sanofi/GSK also generated
341 higher titres of neutralising antibody against the Omicron BA.1 variant compared to other
342 vaccines tested when used as a third dose booster [22].

343 One of the limitations of this study includes, as stated above, the differences in the time
344 interval between the last and booster dose in Groups A and B, thus the two groups could not be
345 compared directly. In cellular immunity assay, we did not perform surface staining and
346 subpopulation gating and thus we could not distinguish between single-variant from dual/multi-
347 variant spike-specific MBCs, as has been shown for mRNA-1273 [23]. The sample size was not
348 sufficient to compare all the endpoints across treatment arms, particularly, the efficacy.

349 In this interim report, we found that heterologous booster with the Beta variant construct
350 vaccine can generate a broad immune response that cross-react with the Omicron variant. The
351 finding support further clinical development of this Beta variant version vaccine.

352

353 **Conflict of Interest Disclosure:**

354 C. E. L., L. T.-C.- L., C.-C. W., W.-H. T., W.-C. L., and C. C. are employees of Medigen Vaccine
355 Biologics Corporation. M.-C. L., N.-C. W., and K.-Y. A. H. declared no conflict of interest.

356 All authors have reviewed and agreed to the final version of the manuscript.

357

358 **Funding/Support:**

359 Medigen Vaccine Biologics Corporation.

360 **Role of the Funder/Sponsor:**

361 Medigen Vaccine Biologics (the study sponsor) had a role in study design, data analysis,
362 and data interpretation, but had no role in data collection, or writing of the clinical report.

363 **Author Contributions:**

364 Concept, design, and leading the clinical trial: C. E. L. and C. C.

365 Acquisition and interpretation of data: M.-C. L., N.-C. W., and K.-Y. A. H.

366 Data analysis and Drafting of the manuscript: C. E. L., L. T.-C. L., and C. C.

367 Vaccine production: C.-C. W., W.-H. T., and W.-C. L.

368 **Data availability**

369 Data sharing is not applicable to this study, as it is an interim analysis of an ongoing clinical
370 trial.

371 **Acknowledgements**

372 We thank the Institute of Biomedical Sciences of Academia Sinica for performing the live
373 virus and pseudovirus neutralization assay.

374


375 **References**

- 376 1. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, *et al.* Covid-19 vaccine
377 effectiveness against the Omicron (B. 1.1. 529) variant. *New England Journal of Medicine.*
378 2022 Apr 21;386(16):1532-46.
- 379 2. Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, *et al.* Omicron escapes the majority of
380 existing SARS-CoV-2 neutralizing antibodies. *Nature.* 2022 Feb;602(7898):657-63.
- 381 3. World Health Organization. Tracking SARS-CoV-2 variants. *Who.int.* 2022. Available from:
382 <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/> [Accessed 25 August 2022].
- 383 4. Lyke KE, Atmar RL, Islas CD, Posavad CM, Szydlo D, *et al.* Rapid decline in vaccine-boosted
384 neutralizing antibodies against SARS-CoV-2 Omicron variant. *Cell Reports Medicine.* 2022 Jul
385 19;3(7):100679.
- 386 5. Qu P, Faraone J, Evans JP, Zou X, Zheng YM, Carlin C, *et al.* Neutralization of the SARS-
387 CoV-2 omicron BA. 4/5 and BA. 2.12. 1 subvariants. *New England Journal of Medicine.* 2022

- 388 Jun 30;386(26):2526-8.
- 389 6. Pfizer. Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates
390 Demonstrate High Immune Response Against Omicron. Pfizer.com. 2022. Available from:
391 [https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-omicron-adapted-covid-19)
392 [omicron-adapted-covid-19](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-omicron-adapted-covid-19) [Accessed 25 August 2022].
- 393 7. Medicines and Healthcare products Regulatory Agency, Government of the United Kingdom.
394 First bivalent COVID-19 booster vaccine approved by UK medicines regulator. Gov.uk. 2022.
395 Available from: [https://www.gov.uk/government/news/first-bivalent-covid-19-booster-vaccine-](https://www.gov.uk/government/news/first-bivalent-covid-19-booster-vaccine-approved-by-uk-medicines-regulator)
396 [approved-by-uk-medicines-regulator](https://www.gov.uk/government/news/first-bivalent-covid-19-booster-vaccine-approved-by-uk-medicines-regulator) [Accessed 25 August 2022].
- 397 8. Kuo TY, Lin MY, Coffman RL, Campbell JD, Traquina P, Lin YJ, *et al.* Development of CpG-
398 adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-
399 19. *Scientific reports*. 2020 Nov 18;10(1):1-0.
- 400 9. Hsieh SM, Chang SC, Cheng HY, Shih SR, Lien CE. Durability and Immunogenicity of
401 Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit
402 SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation
403 Phase 1 Study. *Infectious Diseases and Therapy*. 2022 May 17:1-2.
- 404 10. Kuo TY, Lien CE, Lin YJ, Lin MY, Wu CC, Tang WH, *et al.* Protection of Hamsters
405 Challenged with SARS-CoV-2 Delta Variant after Two Doses of Adjuvanted SARS-CoV-2
406 Stabilized Prefusion Spike Protein (S-2P) and a Single Dose of Beta Variant S-2P. *The Journal*
407 *of infectious diseases*. 2022 Apr 22.
- 408 11. Hsieh SM, Liu MC, Chen YH, Lee WS, Hwang SJ, Cheng SH, *et al.* Safety and
409 immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein
410 vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-
411 controlled phase 2 trial in Taiwan. *The Lancet Respiratory Medicine*. 2021 Dec 1;9(12):1396-
412 406.
- 413 12. Hsieh SM, Liu WD, Huang YS, Lin YJ, Hsieh EF, Lian WC, *et al.* Safety and immunogenicity
414 of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVCCOV1901)
415 Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-
416 escalation study. *EClinicalMedicine*. 2021 Aug 1;38:100989.
- 417 13. Lien CE, Kuo TY, Lin YJ, Lian WC, Lin MY, Liu LT, *et al.* Evaluating the neutralizing ability
418 of a CpG-adjuvanted S-2P subunit vaccine against severe acute respiratory syndrome
419 coronavirus 2 (SARS-CoV-2) variants of concern. *Clinical Infectious Diseases*. 2022 Jun
420 1;74(11):1899-905.
- 421 14. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, *et al.* Neutralizing


- 422 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2
423 infection. *Nature medicine*. 2021 Jul;27(7):1205-11.
- 424 15. World Health Organization. WHO Target Product Profiles for COVID-19 Vaccines. Revised
425 version April 2022. Who.int. 2022. Available from:
426 <https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines>
427 [Accessed 28 August 2022].
- 428 16. Moss P. The T cell immune response against SARS-CoV-2. *Nature immunology*. 2022
429 Feb;23(2):186-93.
- 430 17. Calabrese CM, Husni EM, Moss BM, Fernandez AJ, Jin Y, Kirchner E, Calabrese LH.
431 Breakthrough SARS-CoV-2 infections in immune mediated disease patients undergoing B cell
432 depleting therapy. medRxiv. 2022.02.21.22271289
- 433 18. Muecksch F, Wang Z, Cho A, Gaebler C, Ben Tanfous T, DaSilva J, *et al*. Increased memory B
434 cell potency and breadth after a SARS-CoV-2 mRNA boost. *Nature*. 2022 Jul;607(7917):128-
435 134.
- 436 19. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, *et al*. Effectiveness of mRNA-1273
437 against SARS-CoV-2 Omicron and Delta variants. *Nature Medicine*. 2022 May;28(5):1063-71.
- 438 20. Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK, *et al*. Effectiveness of
439 a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A
440 retrospective cohort study. *The Lancet Regional Health-Americas*. 2022 May 1;9:100198.
- 441 21. Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, *et al*. A Bivalent Omicron-
442 containing Booster Vaccine Against Covid-19. medRxiv. 2022.06.24.22276703
- 443 22. Launay O, Cachanado M, Ngüyen LB, Ninove L, Lachâtre M, Ghezala IB, *et al*.
444 Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine. *New England*
445 *Journal of Medicine*. 2022 July 28;387:374-376.
- 446 23. Gagne M, Moliva JI, Foulds KE, Andrew SF, Flynn BJ, Werner AP, *et al*. mRNA-1273 or
447 mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing
448 responses, and protection from Omicron. *Cell*. 2022 Apr 28;185(9):1556-71.
- 449
- 450
- 451

452 **Figures**



453
454 **Figure 1.** CONSORT flow diagram for the study.

455




456

457 **Figure 2.** Solicited local and systemic adverse events for each of the treatment groups in Groups A

458 and B

459




460

461 **Figure 3.** Immunogenicity of the booster dose. A) neutralising antibody titre against live ancestral

462 (WT) SARS-CoV-2 and Beta variant; B) anti-SARS-CoV-2 spike IgG antibody titre; C) GMT ratio

463 of neutralising antibody titres of V5/V2 (left) and anti-spike IgG titres at V4/V2 and V5/V2 (right).
 464 For (A) and (B), results are expressed as symbols representing GMT and error bars represent 95%
 465 confidence intervals. For (C), results are expressed as mean GMT ratio with error bars representing
 466 95% confidence intervals. Statistical significance was calculated using the Kruskal-Wallis test with
 467 corrected Dunn's multiple comparisons test. * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$, **** = $p <$
 468 0.0001
 469




470
 471 **Figure 4.** Pseudovirus neutralisation assay of pseudovirus with spike proteins of the original SARS-
 472 CoV-2 or Omicron variant (BA.4/BA.5) with serum samples from Visits 2 (baseline) and 5 (2 weeks
 473 after the booster dose). Blue and red symbols show individual titre values, while bars represent
 474 GMTs and error bars represent 95% confidence intervals. Fold differences between GMT's are
 475 shown numerically above the upper dotted line. Dotted lines indicate the starting dilution (20; lower

476 dotted line) and the final dilution (2560; upper dotted line) for the assay, and all values below 20 are
477 tabulated as 10. Statistical significance was calculated using the Kruskal-Wallis test with corrected
478 Dunn's multiple comparisons test. * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$, **** = $p < 0.0001$

479

480



482 **Figure 5.** SARS-CoV-2 spike-specific memory B cell (MBC) response before and after the booster
483 dose. **(A)** Illustration of SARS-CoV-2 spike-specific MBC frequency, measured by ELISpot. In the
484 ELISpot assay, antigen-coated wells were used to assess antigen-specific MBC, PBS-coated wells
485 were used as negative controls, anti-Ig coated wells were used to assess total IgG MBC. The
486 numbers (in italics) of spots and cultured cells incubated in the ELISpot assay were shown below
487 each image. Each spot represents an antibody-secreting cell. The frequency of antigen-specific IgG
488 MBC was calculated as the percentage of total IgG MBC. Subject 02-023 is an adult who had two
489 prior doses of MVC-COV1901 and received a booster dose of MVC-COV1901 containing a Beta
490 variant spike of 15 mcg. V2, the vaccination day; V4, 14 days after the booster dose. **(B)** spike-
491 specific MBC frequency in the peripheral blood was measured in those with two (group A) and three
492 (group B) initial doses of MVC-COV1901, before (V2) and 14 days (V4) after the booster dose,
493 with memory B cell ELISpot assay. Wild type (WT), Beta, and Omicron BA.1 spike-specific IgG,
494 IgM or IgA MBC frequencies were shown in mean \pm SEM in the figure. Each symbol represents a
495 sample (subject). **(C)** spike-specific MBC frequency in the subgroups, i.e., booster dose with MVC-
496 COV1901 containing Wuhan wild type spike, booster dose with MVC-COV1901 containing Beta
497 variant spike 15 mcg, and booster dose with MVC-COV1901 containing Beta variant spike 25 mcg,
498 of group A and B. Wild type (WT), Beta, and Omicron BA.1 spike-specific IgG, IgM or IgA MBC
499 frequencies were shown in mean \pm SEM in the figure. Each symbol represents a sample (subject).
500 **(D)** Relationship of spike-specific IgG MBC frequency and serological neutralisation titre with wild
501 type and Omicron variant BA.4/BA.5 SARS-CoV-2 pseudovirus among group A and B subjects.
502 Linear regression was used to model the relationship between two variables. pNT, pseudovirus
503 neutralisation titre. Mann-Whitney test was used to compare MBC frequencies at two-time points.
504 *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ns, not significant.
505
506


507 **Tables**

508

509 **Table 1.** Demographics and baseline characteristics of the participants for Group A and Group B.


	Group A (N=45)		
	MVC-COV1901 (15 mcg)	MVC-COV1901 (15 mcg, beta)	MVC-COV1901 (25 mcg, beta)
n	15	15	15
age mean (SD)	36.9 (9.25)	34.7 (7.71)	39.5 (9.16)
Male	53.3%	73.3%	60.0%
BMI	24.991	24.710	26.215
HIV-positive	0	0	0
HBsAg-positive	0	0	0
Anti-HCV antibody-positive	0	0	0
Cardiovascular disease	0	0	0
Cerebrovascular disease	0	0	0
Malignancy	0	0	0
HbA1c higher than the normal range	0	1 (6.7%)	0
1, 2 dose interval (days) mean (SD)	33.1 (6.55)	34.5 (4.21)	32.6 (4.98)
2, 3 dose interval (days) mean (SD)	-	-	-
Last dose interval (days) mean (SD)	270.6 (101.06)	223.3 (36.98)	294.5 (90.88)
	Group B (N=61)		
	MVC-COV1901 (15 mcg)	MVC-COV1901 (15 mcg, beta)	MVC-COV1901 (25 mcg, beta)
n	21	21	20
age mean (SD)	36.8 (9.24)	38.6 (7.53)	38.0 (8.98)
Male	38.1%	47.6%	55.0%
BMI	24.440	24.210	24.606
HIV-positive	0	0	0
HBsAg-positive	0	0	0
Anti-HCV antibody-positive	0	0	0
Cardiovascular disease	0	1 (4.8%)	0
Cerebrovascular disease	1 (4.8%)	0	0
Malignancy	0	0	1 (5.0%)
HbA1c higher than the normal range	2 (9.5%)	0	1 (5.0%)
1, 2 dose interval (days) mean (SD)	38.7 (7.80)	37.5 (3.04)	37.6 (2.78)
2, 3 dose interval (days) mean (SD)	111.6 (11.82)	113.2 (16.44)	109.2 (9.41)
Last dose interval (days) mean (SD)	120.9 (12.20)	128.0 (28.05)	123.2 (10.32)

510



Group A


Group B




Grade 1
 Grade 2
 Grade 3

A

□ V2 (Baseline)
 ■ V5 (4 weeks after booster)

**B**

■ V2 (Baseline)
 □ V4 (2 weeks after booster)
 ■ V5 (4 weeks after booster)

**Neutralising assay****Anti-spike IgG assay****C**

□ Ancestral (WT) strain
 ■ Beta variant

□ V4/V2
 ■ V5/V2

